Oleclumab (MEDI9447) EGFRm NSCLC Novel Combination Study



Status:Recruiting
Conditions:Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 127
Updated:3/13/2019
Start Date:May 8, 2018
End Date:March 3, 2022
Contact:AstraZeneca Clinical Study Information Center
Email:information.center@astrazeneca.com
Phone:1-877-240-9479

Use our guide to learn which trials are right for you!

A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC

The objective of this study is to investigate the safety, tolerability and antitumor activity
of novel combination therapies administered in subjects with advanced EGFRm NSCLC


Inclusion Criteria:

1. Age ≥ 18

2. ECOG Performance Status of 0 or 1

3. Weight ≥ 35 kg

4. Diagnosed with histologically or cytologically confirmed locally advanced/metastatic
NSCLC with EGFR mutation

- For Arm A: must have received 1 prior line of therapy with an EGFR TKI and
confirmed T790M negative

- For Arm B: must have received at least 2 but not more than 4 prior lines of
therapy.

Exclusion Criteria:

1. Receipt of an EGFR TKI within 14 days of the first dose of study treatment.

2. Receipt of any conventional or investigational anticancer therapy not otherwise
specified within 21 days of the planned first dose.

3. Prior receipt of any investigational immunotherapy. Subjects may have received agents
that have local health authority approval for the disease indication

4. Concurrent enrollment in another therapeutic clinical study. Enrollment in
observational studies will be allowed

5. Subjects with a history of venous thrombosis within the past 3 months

6. Subjects with prior history of myocardial infarction, transient ischemic attack, or
stroke in the last 6 months

7. Active or prior documented autoimmune or inflammatory disorders within the past 3
years prior to the start of treatment

8. Other invasive malignancy within 2 years.

9. Untreated CNS metastatic disease, leptomeningeal disease, or cord compression

10. Current or prior use of immunosuppressive medication within 14 days prior to the first
dose

Additional Exclusion Criteria for Arm A

1. Concurrent treatment (or inability to stop therapy) with medications or herbal
supplements known to be potent inducers of CYP3A4

2. Subject has a history of ILD, drug-induced ILD, radiation pneumonitis that required
steroid treatment, or any evidence of clinically active ILD.

3. Subject requires continuous supplemental oxygen for any reason.

Additional Exclusion Criteria for Arm B

1. Herbal preparations/medications are not allowed throughout the study

2. History of seizures excluding those that occurred due to previously untreated CNS
metastasis
We found this trial at
12
sites
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
New Haven, CT
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
?
mi
from
Seoul,
Click here to add this to my saved trials